Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 30;11(1):602.
doi: 10.1038/s41467-020-14290-4.

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

Jason B Williams #  1 , Shuyin Li #  1 , Emily F Higgs  1 , Alexandra Cabanov  1 , Xiaozhong Wang  2 , Haochu Huang  1 , Thomas F Gajewski  3   4   5
Affiliations

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

Jason B Williams et al. Nat Commun. .

Abstract

PD-1/PD-L1 blockade can promote robust tumor regression yet secondary resistance often occurs as immune selective pressure drives outgrowth of resistant tumor clones. Here using a genome-wide CRISPR screen in B16.SIY melanoma cells, we confirm Ifngr2 and Jak1 as important genes conferring sensitivity to T cell-mediated killing in vitro. However, when implanted into mice, these Ifngr2- and Jak1-deficient tumors paradoxically are better controlled immunologically. This phenotype maps to defective PD-L1 upregulation on mutant tumor cells, which improves anti-tumor efficacy of CD8+ T cells. To reconcile these observations with clinical reports of anti-PD-1 resistance linked to emergence of IFN-γ signaling mutants, we show that when mixed with wild-type tumor cells, IFN-γ-insensitive tumor cells indeed grow out, which depends upon PD-L1 expression by wild-type cells. Our results illustrate the complexity of functions for IFN-γ in anti-tumor immunity and demonstrate that intratumor heterogeneity and clonal cooperation can contribute to immunotherapy resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. A genome-wide CRISPR/Cas9 screen identifies Ifngr2 and Jak1 as essential for T cell-mediated killing of B16.SIY cells in vitro.
a In vitro assessment for loss of IFN-γ signaling. Tumor cell clones were stimulated with 10 ng/mL IFN-γ for 16 h and measured for H-2Kb upregulation by flow cytometry. b Genotype of IFNγR2- and Jak1-mutant cell lines. Colors highlight features as follows: red, gRNA sequence; green, PAM; blue, nucleotide insertion. c Relative resistance of IFNγR2- and Jak1-mutant tumor cells to T cell-mediated killing in vitro. Tumor cells were incubated with pre-primed 2 C T cells for 24 h and remaining cells were measured by live/dead staining. n = 7 assays; data are pooled from three independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a two-way ANOVA Bonferroni post-hoc test (c). *p < 0.05.
Fig. 2
Fig. 2. IFNγR2- and Jak1-mutant tumors are spontaneously controlled in vivo.
a Tumor growth curves of WT, IFNγR2-, and Jak1-mutant tumors. n = 10 mice; data are pooled from two independent experiments. b, c Representative histogram showing restored IFN-γ signaling after retroviral reintroduction of IFNγR2 (b) or Jak1 (c). Tumor cells were stimulated with 10 ng/mL IFN-γ for 16 h and measured for H-2Kb upregulation by flow cytometry. n = 4 stimulations; data is representative of two independent experiments. d, e Restoration of progressive tumor growth of IFNγR2 Mut.1 tumors with reintroduced IFNγR2 (d) and Jak1 Mut.1 tumors with reintroduced Jak1 (e). n = 15 mice (WT EV, IFNγR2 Mut.1, and IFNγR2 Mut.1 + IFNγR2), n = 10 mice (Jak1 Mut.2), n = 5 mice (Jak1 Mut.2 + Jak1); data are pooled from three (d) or one (e) independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a two-way ANOVA Bonferroni post-hoc test (a, d, e). *** p < 0.001.
Fig. 3
Fig. 3. CD8+ T cells are required for the spontaneous control of IFN-γ-insensitive tumors.
a Tumor outgrowth of WT, IFNγR2 Mut.1, and Jak1 Mut.2 tumors in Rag2–/– mice. n = 6 mice; data are pooled from two independent experiments. b Tumor outgrowth of WT, IFNγR2 Mut.1 CD8+ T cell-depleted mice. Mice received 200 μg of anti-CD8α (clone YTS169.4). n = 8 mice (WT and IFNγR2 Mut.1) and n = 7 mice (Jak1 Mut.1); data are pooled from two independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a two-way ANOVA Bonferroni post-hoc test (a, b). *** p < 0.001.
Fig. 4
Fig. 4. The antitumor CD8+ T cell response is augmented against IFN-γ-insensitive tumors.
a Frequency of splenic IFN-γ-secreting T cells in response to SIY measured by enzyme-linked immunospot (ELISPOT). Splenocytes were isolated from mice on day 7 after tumor engraftment and cultured with 100 μM SIY for 18 h. n = 21 mice (WT), n = 20 mice (IFNγR2 Mut.1), and n = 10 mice (Jak1 Mut.1); data are pooled from 4 (IFNγR2 Mut.1) or 2 (Jak1 Mut.1) independent experiments. b Representative flow cytometry plots (left) and cumulative data (right) of H-2Kb/SIY+ CD8+ TILs isolated on day 7 after engraftment of WT, IFNγR2 Mut.1, and Jak1 Mut.1 tumor cells. n = 33 mice (WT), n = 34 mice (IFNγR2 Mut.1), and n = 18 mice (Jak1 Mut.1); data are pooled from six (IFNγR2 Mut.1) or four (Jak1 Mut.1) independent experiments. c As in b but with IFNγR2 Mut.1 tumors with reintroduced IFNγR2. n = 15 mice (WT and IFNγR2 Mut.1), n = 14 mice (IFNγR2 Mut.1 + IFNγR2); data are pooled from three independent experiments. d As in b but with Jak1 Mut.1 tumors with reintroduced Jak1. n = 17 mice (WT), n = 13 mice (Jak1 Mut.1), and n = 10 mice (Jak1 Mut.1 + Jak1); data are pooled from three independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a Kruskal-Wallis (non-parametric) test (a–d). *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 5
Fig. 5. A complex genetic program is induced by IFN-γ signaling in tumor cells that includes PD-L1.
a Volcano plot of differentially expressed genes (DEGs) from IFNγR2- and Jak1-mutant tumor cells compared to WT tumor cells. Tumor cells were sorted on day 7 after tumor engraftment. b The number of unique and shared DEGs between IFNγR2- and Jak1-mutant tumor cells. c Selected downregulated genes in IFNγR2- or Jak1-mutant tumor cells compared to WT tumor cells grouped by biological pathway. Numerical values in heat map are expressed as Z-scores.
Fig. 6
Fig. 6. Re-establishment of PD-L1 restores progress tumor growth of IFN-γ-insensitive tumors.
a–c Representative histograms of PD-L1 expression on tumor cells (a) or CD45+ MHCII+ APCs (b) from IFNγR2 Mut.1, Jak1 Mut.1, or WT tumors and summary of percent PD-L1+ tumor cells (c). Analysis was performed on day 7 after tumor engraftment. n = 15 mice; data are pooled from three independent experiments. d mRNA expression of PD-L1 from sorted tumor cells on day 7 after tumor engraftment. n = 8 mice; data are pooled from two independent experiments. e Representative histogram of PD-L1 expression after retroviral introduction of PD-L1 in IFNγR2- and Jak1-mutant tumor cells in vitro. Expression of PD-L1 was compared to WT tumor cells with or without IFN-γ stimulation. f Tumor outgrowth curves when PD-L1 was re-expressed in IFNγR2- and Jak1-mutant tumor cells. n = 10 mice (WT, IFNγR2 Mut1, Jak1 Mut1, and IFNγR2 Mut.1 + PD-L1) and n = 5 mice (Jak1 Mut.1 + PD-L1); data are pooled from two independent experiments (IFNγR2) or from one experiment (Jak1). g Tumor outgrowth curves when H-2Kb was deleted in IFNγR2-mutant tumor cells. n = 10 mice (WT and IFNγR2 Mut.1), n = 15 mice (IFNγR2 Mut.1 H-2Kb Mut), and n = 5 mice (H-2Kb Mut); data are pooled from two independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a Kruskal-Wallis (non-parametric) test (b, c) and a two-way ANOVA Bonferroni post-hoc test (f, g). *p < 0.05, ***p < 0.001.
Fig. 7
Fig. 7. When mixed with WT tumor cells, IFN-γ-insensitive tumor cells selectively grow out following to anti-PD-L1 therapy in vivo.
a Tumor outgrowth of mixed WT and IFNγR2-mutant tumors with and without anti-PD-L1 therapy. n = 24 mice (WT:WT), n = 14 mice (WT:WT + anti-PD-L1), n = 25 mice (IFNγR2 Mut.1:WT), and n = 28 (WT:IFNγR2 Mut.1 + anti-PD-L1); data are pooled from four independent experiments. b Log2(BFP/ZsGreen) fold-change after anti-PD-L1 therapy. c Fold-change of mixed tumors in Rag2–/– mice. n = 9 mice (WT:WT) and n = 10 mice (WT:IFNγR2 Mut.1); data are pooled from two independent experiments. d Representative flow plots of tumor composition of mixed WT:IFNγR2-mutant tumors in the context of a strong and weak immune response. e Tumor composition of mixed tumors from individual mice treated with anti-PD-L1. f Correlation between H-2Kb/SIY+ CD8+ TILs and selection for WT-BFP or IFNγR2 Mut.1 BFP. For (b, e, f) n = 13 mice (WT:WT + anti-PD-L1) and n = 15 mice (WT:IFNγR2 Mut.1 + anti-PD-L1); data are pooled from five independent experiments. Results are expressed as mean ± s.e.m. Statistical significance was determined by a two-way ANOVA Bonferroni post-hoc test (a) and a Kruskal-Wallis (non-parametric) test (b, c). Least squares regression was performed in (f). **p < 0.01, ***p < 0.001.
Fig. 8
Fig. 8. The antitumor effects of IFN-γ on WT tumor cells drives selection for IFNγR2-mutant tumor cells.
a and b Correlation between the concentration of intratumoral IFN-γ and the fold-change in the frequency of BFP+ versus ZsGreen+ tumor cells (a) and the total number of H-2Kb/SIY+ CD8+ TILs (b). c Correlation between the total number of H-2Kb/SIY+ CD8+ TILs and fold-change in the frequency of BFP+ versus ZsGreen+ tumor cells. a–c Tumors were analyzed on day 14 after tumor inoculation. All data were log2-transformed. n = 60 mice (a, c) and n = 49 mice (b); data are pooled from five independent experiments. d Concentration of IFN-γ after CD8+ T cell depletion. n = 35 mice (no treatment) and n = 15 mice (anti-CD8α) e Correlation between intratumoral IFN-γ and log2(BFP/ZsGreen) fold-change in the absence of CD8+ T cells. Mice received 200 μg anti-CD8a (clone YTS169.4) on days -1 and 7. Tumors were analyzed on day 14. n = 10 mice; data are pooled from two independent experiments. f Fold-change in BFP+ versus ZsGreen+ tumor cells after administration of recombinant mouse IFN-γ. 50 μg of IFN-γ was administered i.p. on days 7, 10, 13, and 16. Tumor cell composition was analyzed on day 18. n = 10 mice (WT:WT and WT:WT + IFN-γ), n = 12 mice (WT:IγR2), and n = 15 mice (WT:IγR2 + IFN-γ); data are pooled from two independent experiments. g Tumor outgrowth of mixed WT and PD-L1-mutant tumors. n = 10 mice; data are pooled from two independent experiments. Results are expressed as mean ± s.e.m. Least squares regression was performed in (a–c, e). Statistical significance was determined by a Mann-Whitney test (f) and a two-way ANOVA Bonferroni post-hoc test (g). *p < 0.05, **p < 0.01, ***p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer. 2018;6:8. doi: 10.1186/s40425-018-0316-z. - DOI - PMC - PubMed
    1. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920. doi: 10.1016/S0140-6736(16)00561-4. - DOI - PMC - PubMed
    1. Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562. doi: 10.1038/nature13904. - DOI - PubMed
    1. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;366:2455–2465. doi: 10.1056/NEJMoa1200694. - DOI - PMC - PubMed
    1. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443–2454. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed

Publication types